Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder
Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day or 90mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
Phase:
PHASE2
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)